StreetInsider.com News Articles

Benitec BioPharma (BNTC) Reiterated at Market Outperform by Citizens After OPMD Data

Wed, 25 Feb 2026 05:10:54 +0000

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $22.00 price target on Benitec BioPharma (NASDAQ: BNTC).

The analyst commented, "A preview of data from the first OPMD patient treated with high-dose BB-301 should be closely watched. Given all low-dose patients were responders, at the high dose we are looking for signs of faster response kinetics and the potential for deeper responses versus the low dose. The long-term update for the first patient, at 24 months post dose, is an important milestone for BB-301 and begins to provide data points that support extended durability. This is a key update ahead

Benitec Biopharma to present BB-301 clinical data at muscular dystrophy conference

Mon, 23 Feb 2026 07:00:46 +0000

Benitec Biopharma Inc. (NASDAQ: BNTC) announced that its late-breaking abstract for the BB-301 Phase 1b/2a clinical study has been accepted for presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference on March 9, 2026, in Orlando, Florida.

The poster presentation will include 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first Cohort 1 patient, and interim clinical study results for the first Cohort 2 patient. The study involves patients with Oculopharyngeal Muscular Dystrophy (OPMD) and moderate dysphagia.

The presentation, titled "Durable Responses to Low-Dose BB-301 in Oculopharyngeal Muscular Dystrophy at 12- and

Benitec Biopharma to present BB-301 clinical data at muscular dystrophy conference

Mon, 23 Feb 2026 07:00:46 +0000

The presentation, titled "Durable Responses to Low-Dose BB-301 in Oculopharyngeal Muscular Dystrophy at 12- and

Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference

Mon, 23 Feb 2026 07:00:00 +0000

-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first Cohort 1 Patient, and interim clinical study results for the first Cohort 2 Patient will be reported in a late-breaking poster presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference on March 9, 2026-

HAYWARD, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary

Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference

Mon, 23 Feb 2026 07:00:00 +0000

Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference

Mon, 23 Feb 2026 07:00:00 +0000

Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference

Mon, 23 Feb 2026 07:00:00 +0000